Assistant Professor Natchaya Vanwong, MT, Ph.D.

Education

2012-2017 M.Sc.-Ph.D. (Clinical Pathology), Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand 2007-2011 B.Sc. (Medical Technology, Honors), Thammasat University, Thailand

Training

Research Training: “Franco-Thai Mobility Programme/PHC SIAM” in Department of Pharmacology, Toxicology and Pharmacovigilance at the Univeristy Hospital of Limoges, France

Professional Experience

Pharmacogenomics and Precision Medicine

Publications

Research Articles:

1. Atasilp C, Lenavat R, Vanwong N, Chansriwong P, Sirachainan E, Reungwetwattana T, Jinda P, Aiempradit S, Sirilerttrakul S, Chamnanphon M, Puangpetch A, Sankuntaw N, Satapornpong P, Sukasem C. Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients. Front Oncol. 2022 Jul 15;12:916650.
2. Atasilp C, Biswas M, Jinda P, Nuntharadthanaphong N, Rachanakul J, Hongkaew Y, Vanwong N, Saokaew S, Sukasem C. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. Clin Transl Sci. 2022 Jul;15(7):1613-1633.
3. Atasilp C, Kanjanapipak J, Vichayaprasertkul J, Jinda P, Tiyasirichokchai R, Srisawasdi P, Prempunpong C, Chamnanphon M, Puangpetch A, Vanwong N, Klongthalay S, Jantararoungtong T, Sukasem C. Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population. BMC Pediatr. 2022 May 2;22(1):243.
4. Vanwong N, Tipnoppanon S, Na Nakorn C, Srisawasdi P, Rodcharoen P, Medhasi S, Chariyavilaskul P, Siwamogsatham S, Vorasettakarnkij Y, Sukasem C. Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia. Pharmgenomics Pers Med. 2022 Feb 17;15:119-130.
5. Vanwong N, Sukasem C, Unaharassamee W, Jiratjintana N, Na Nakorn C, Hongkaew Y, Puangpetch A. Associations of the SREBF2 Gene and INSIG2 Polymorphisms with Obesity and Dyslipidemia in Thai Psychotic Disorder Patients Treated with Risperidone. J Pers Med. 2021 Sep 22;11(10):943.
6. Vanwong N, Puangpetch A, Unaharassamee W, Jiratjintana N, Na Nakorn C, Hongkaew Y, Sukasem C. Effect of 5-HT2C receptor gene polymorphism (HTR2C-759C/T) on metabolic adverse effects in Thai psychiatric patients treated with risperidone. Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):806-813.
7. Vanwong N, Ngamsamut N, Nuntamool N, Hongkaew Y, Sukprasong R, Puangpetch A, Limsila P, Sukasem C. Risperidone-Induced Obesity in Children and Adolescents with Autism Spectrum Disorder: Genetic and Clinical Risk Factors. Front Pharmacol. 2020 Nov 6;11:565074.
8. Chamnanphon M, Gaedigk A, Vanwong N, Nuntamool N, Hongkaew Y, Puangpetch A, Sukasem C. “CYP2D6 genotype analysis of a Thai population: platform comparison.” Pharmacogenomics. 2018 Jul 11.
9. Hongkaew Y, Medhasi S, Pasomsub E, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, Limsila P, Suthisisang C, Wilffert B, Sukasem C. “UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.” Pharmacogenomics J. 2018 Jun 29.
10. Sukasem C, Vanwong N, Srisawasdi P, Ngamsamut N, Nuntamool N, Hongkaew Y, Puangpetch A, Chamkrachangpada B, Limsila P. “Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder.” Basic Clin Pharmacol Toxicol. 2018 Jul;123(1):42-50.
11. Nuntamool N, Ngamsamut N, Vanwong N, Puangpetch A, Chamnanphon M, Hongkaew Y, Limsila P, Suthisisang C, Wilffert B, Sukasem C., “Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents.” Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):316-324.
12. Srisawasdi P, Vanwong N, Hongkaew Y, Puangpetch A, Vanavanan S, Intachak B, et al. Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. Clin Biochem. 2017 Feb 3. pii: S0009-9120(16)30511-2.
13. Vanwong N, Srisawasdi P, Ngamsamut N, Nuntamool N, Puangpetch A, Chamkrachangpada B, Hongkaew Y, Limsila P, Kittitharaphan W, Sukasem C. Hyperuricemia in Children and Adolescents with Autism Spectrum Disorder Treated with Risperidone: The Risk Factors for Metabolic Adverse Effects. Front Pharmacol. 2017 Jan 5;7:527.
14. Vanwong N, Ngamsamut N, Medhasi S, Puangpetch A, Chamnanphon M, Tan-Kam T, Hongkaew Y, Limsila P, Sukasem C. Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2016 Jan, Volume 26, Number x, 2016
15. Vanwong N, Ngamsamut N, Hongkaew Y, Nuntamool N, Puangpetch A, Chamnanphon M, Sinrachatanant A, Limsila P, Sukasem C. Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. Drug Metabolism and Pharmacokinetics. 2016 Apr, Vol. 31, No. 2: 156-162.
16. Vanwong N, Prommas S, Puangpetch A, Hongkaew Y, Nuntamool N, Nakorn CN, Ngamsamut N, Limsila P, Sukasem C. Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders. J Clin Lab Anal. 2016 Jun 26.
17. Vanwong N, Medhasi S, Pongchaidecha M, Ngamsamut N, Puangpetch A, Chamnanphon M, Chamkrachchangpada B, Tan-kam T, Hongkaew Y, Limsila P, Sukasem C. Pharmacogenetics and Clinical Risk Factors for Risperidone-Related Weight Gain in Thai Autistic Spectrum Disorders. Thai J Pharmacol; Vol. 36: No. 1, 2014
18. Medhasi S, Pinthong D, Pasomsub E, Vanwong N, Ngamsamut N, Puangpetch A, et al. Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients. Front Pharmacol. 2016 Dec 2;7:475.
19. Medhasi S, Pasomsub E, Vanwong N, Ngamsamut N, Puangpetch A, Chamnanphon M, Hongkaew Y, Limsila P, Pinthong D, Sukasem C. Clinically relevant genetic variants of drugmetabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder. Neuropsychiatr Dis Treat. 2016 Apr 13;12:843-51.
20. Ngamsamut N, Hongkaew Y, Vanwong N, Srisawasdi P, Puangpetch A, Chamkrachangpada B, Tan-Khum T, Limsila P, Sukasem C. 9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder. Basic Clin Pharmacol Toxicol. 2016 Sep;119(3):267-72.
21. Sukasem C, Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, Chamkrachchangpada B, Sinrachatanant A, Limsila P. Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders. J Clin Psychopharmacol. 2016 Apr;36(2):141-6.
22. Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, Chamkrachchangpada B, Tan-Kam T, Limsila P, Sukasem C. Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone. Neuropsychiatr Dis Treat. 2015 Jan 22;11:191-6. doi: 10.2147/NDT.S76276.
23. Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, Chamkrachchangpada B, Tan-kam T, Hongkaew Y, Limsila P, Sukasem C. Serum prolactin level in Thai children and adolescents with autistic spectrum disorder on long term risperidone treatments. Thai J Pharmacol; Vol. 36: No. 1, 2014.

Review article:

1. Biswas M‡, Vanwong N‡, Sukasem C. Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder. Pharmacogenomics. 2022 Apr 28. ‡Co-first authors
2. Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C. CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmgenomics Pers Med. 2016 Dec 1;9:131-147.